Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)
NCT Number:
NCT04928846
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lung
Study Objectives:
The primary objective is to determine if telisotuzumab vedotin improves progression-free survival (PFS) per ICR assessment and/or Overall Survival (OS) compared to docetaxel in the following nested populations: Subjects with c-Met high overexpressing, EGFR wildtype, nonsquamous NSCLC and all subjects with c-Met overexpressing, EGFR wildtype, nonsquamous NSCLC
Study Documents
(MUSC NetID required for document access)